Angelalign Technology (HKG:6699) Full Year 2024 Results
Key Financial Results
- Revenue: US$268.8m (up 28% from FY 2023).
- Net income: US$12.1m (up 61% from FY 2023).
- Profit margin: 4.5% (up from 3.6% in FY 2023). The increase in margin was driven by higher revenue.
- EPS: US$0.072 (up from US$0.045 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Angelalign Technology Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 7.4%. Earnings per share (EPS) also surpassed analyst estimates by 9.0%.
The primary driver behind last 12 months revenue was the Mainland China segment contributing a total revenue of US$188.2m (70% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to US$105.0m (62% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$12.5m. Explore how 6699's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Hong Kong.
Performance of the Hong Kong Medical Equipment industry.
The company's shares are up 6.4% from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Angelalign Technology's balance sheet and an in-depth analysis of the company's financial position.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.